11 research outputs found

    HIV status, knowledge and prevention of cervical cancer amongst adolescent girls and women : a secondary data analysis

    Get PDF
    TABLES AND FIGURES: TABLE 1: baseline characteristics of female ZDHS 2015 used in the analysis. TABLE 2: profiles of women whoever or never heard about cervical cancer. TABLE 3: profiles of women who were ever or never screened for cervical cancer. FIGURE 1: A) HIV in females; B) prevalence of knowledge about cervical cancer; and C) prevalence of cervical cancer testingINTRODUCTION : the objective of this manuscript was to describe the knowledge profiles and determinants of cervical cancer screening among HIV positive and negative adolescent girls and women in Zimbabwe. METHODS : we conducted secondary statistical data analysis to explore the determinants of cervical cancer screening among HIV positive and negative adolescent girls and women using Zimbabwe Demographic Health survey for 2015-16. RESULTS : a total of 9054 adolescent girls aged 15-19, and women aged 20-49 were included in the analysis and the majority (63%) of them resided in rural areas. More than two-thirds (65.9%) had attained secondary level of education. The majority (41.3%) of the adolescent girls and women belonged to the Apostolic sect. A number of key determinants have been identified for being ever screened for cervical cancer. The odds of being ever being screened increased by age, OR(CI) 4.38 (3.22-5.94), p<0.001 for women who are 40 years and older when compared to adolescent and young woman who are between 15-24 years. CONCLUSION : our study reports significant programmatic gaps in the provision of cervical cancer screening and treatment services in the country. The nascent Zimbabwe cervical cancer screening and treatment progamme will benefit from expansion of the number of facilities offering the services and the provision of more efficient health education to adolescent women and girls.http://www.panafrican-med-journal.comam2023School of Health Systems and Public Health (SHSPH

    Understanding the role of intimate partner violence on HIV transmission in Zimbabwe: Secondary data analysis of data from the Zimbabwe demographic survey 2015-2016

    Get PDF
    Background: Gender-based violence (GBV) has been shown to have significant and long-lasting impacts on women’s physical and mental health. It is, therefore, important to study its occurrence in a population and its intersect with infectious diseases such as HIV to inform the wider health promotion agenda. This study aimed to determine the association between GBV and HIV status in women and adolescent girls in Zimbabwe. Methods: A secondary data analysis of data from a cross-sectional Zimbabwe Demographic and Health Survey (ZDHS) was conducted. Statistical analysis was employed to establish the association between GBV and HIV status. Geospatial mapping was conducted using a kernel smoothing method was employed to generate a continuous kernel density surface to illustrate the local spatial variations of female HIV and GBV prevalence. Results: Women and adolescent girls suffering emotional GBV, such as those subjected to humiliation by their husbands or partners, were 1.45 (1.14-1.84) [OR (95% CIs)] times more likely to be HIV positive than those who were never humiliated. The same was true for women and adolescent girls whose husbands or partners threatened to harm them or someone they love, 1.33 (1.04-1.68). There is a relationship between women’s HIV status and intimate partner aggression, such as when their partners pushed, shook, or threw something at them or physically abused them. This was also the case for those who reported that partners kicked, dragged, or beat them, tried to choke or burn them on purpose, or threatened or attacked them with a knife, gun, or other weapons. Women who experienced forced sexual violence with threats were more likely 1.61 (1.08-2.41), to be HIV positive than those women who did not experience the same. Conclusion: GBV is widely spread in Zimbabwe. There is a need for the government to implement creative strategies to reach out to survivors, especially those that are forced to have unprotected sex and are at increased risk of HIV acquisition. This manuscript raises issues that can be addressed by robust health promotion strategies to reduce the impact of the syndemic of GBV and HIV acquisition in Zimbabwe

    Understanding the role of intimate partner violence on HIV transmission in Zimbabwe : secondary data analysis of data from the Zimbabwe demographic survey 2015-2016

    Get PDF
    BACKGROUND : Gender-based violence (GBV) has been shown to have significant and longlasting impacts on women’s physical and mental health. It is, therefore, important to study its occurrence in a population and its intersect with infectious diseases such as HIV to inform the wider health promotion agenda. This study aimed to determine the association between GBV and HIV status in women and adolescent girls in Zimbabwe. METHODS : A secondary data analysis of data from a cross-sectional Zimbabwe Demographic and Health Survey (ZDHS) was conducted. Statistical analysis was employed to establish the association between GBV and HIV status. Geospatial mapping was conducted using a kernel smoothing method was employed to generate a continuous kernel density surface to illustrate the local spatial variations of female HIV and GBV prevalence. RESULTS : Women and adolescent girls suffering emotional GBV, such as those subjected to humiliation by their husbands or partners, were 1.45 (1.14-1.84) [OR (95% CIs)] times more likely to be HIV positive than those who were never humiliated. The same was true for women and adolescent girls whose husbands or partners threatened to harm them or someone they love, 1.33 (1.04-1.68). There is a relationship between women’s HIV status and intimate partner aggression, such as when their partners pushed, shook, or threw something at them or physically abused them. This was also the case for those who reported that partners kicked, dragged, or beat them, tried to choke or burn them on purpose, or threatened or attacked them with a knife, gun, or other weapons. Women who experienced forced sexual violence with threats were more likely 1.61 (1.08-2.41), to be HIV positive than those women who did not experience the same. CONCLUSION : GBV is widely spread in Zimbabwe. There is a need for the government to implement creative strategies to reach out to survivors, especially those that are forced to have unprotected sex and are at increased risk of HIV acquisition. This manuscript raises issues that can be addressed by robust health promotion strategies to reduce the impact of the syndemic of GBV and HIV acquisition in Zimbabwe.https://hpp.tbzmed.ac.ir/am2024School of Health Systems and Public Health (SHSPH)SDG-03:Good heatlh and well-beingSDG-05:Gender equalit

    Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics : a multicentre economic evaluation

    Get PDF
    CITATION: Pooran, A., et al. 2019. Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics : a multicentre economic evaluation. The Lancet Global Health, 7(6):E798-E807. doi:10.1016/S2214-109X(19)30164-0The original publication is available at https://www.thelancet.com/journals/langlo/homeBackground: Rapid on-site diagnosis facilitates tuberculosis control. Performing Xpert MTB/RIF (Xpert) at point of care is feasible, even when performed by minimally trained health-care workers, and when compared with point-of-care smear microscopy, reduces time to diagnosis and pretreatment loss to follow-up. However, whether Xpert is cost-effective at point of care remains unclear. Methods: We empirically collected cost (US,2014)andclinicaloutcomedatafromparticipantspresentingtoprimaryhealth−carefacilitiesinfourAfricancountries(SouthAfrica,Zambia,Zimbabwe,andTanzania)duringtheTB−NEATtrial.Costsweredeterminedusinganbottom−upingredientsapproach.Effectivenessmeasuresfromthetrialincludednumberofcasesdiagnosed,initiatedontreatment,andcompletingtreatment.Theprimaryoutcomewastheincrementalcost−effectivenessofpoint−of−careXpertrelativetosmearmicroscopy.Thestudywasperformedfromtheperspectiveofthehealth−careprovider.Findings:Usingdatafrom1502patients,wecalculatedthatthemeanXpertunitcostwaslowerwhenperformedatacentralisedlaboratory(LabXpert)ratherthanatpointofcare(, 2014) and clinical outcome data from participants presenting to primary health-care facilities in four African countries (South Africa, Zambia, Zimbabwe, and Tanzania) during the TB-NEAT trial. Costs were determined using an bottom-up ingredients approach. Effectiveness measures from the trial included number of cases diagnosed, initiated on treatment, and completing treatment. The primary outcome was the incremental cost-effectiveness of point-of-care Xpert relative to smear microscopy. The study was performed from the perspective of the health-care provider. Findings: Using data from 1502 patients, we calculated that the mean Xpert unit cost was lower when performed at a centralised laboratory (Lab Xpert) rather than at point of care (23·00 [95% CI 22·12–23·88] vs 28⋅03[26⋅19–29⋅87]).Per1000patientsscreened,andrelativetosmearmicroscopy,point−of−careXpertcostanadditional28·03 [26·19–29·87]). Per 1000 patients screened, and relative to smear microscopy, point-of-care Xpert cost an additional 35 529 (27 054–40 025) and was associated with an additional 24·3 treatment initiations ([–20·0 to 68·5]; 1464pertreatment),63⋅4same−daytreatmentinitiations([27⋅3–99⋅4];1464 per treatment), 63·4 same-day treatment initiations ([27·3–99·4]; 511 per same-day treatment), and 29·4 treatment completions ([–6·9 to 65·6]; 1211percompletion).Xpertcostsweremostsensitivetotestvolume,whereasincrementaloutcomesweremostsensitivetothenumberofpatientsinitiatingandcompletingtreatment.Theprobabilityofpoint−of−careXpertbeingcost−effectivewas901211 per completion). Xpert costs were most sensitive to test volume, whereas incremental outcomes were most sensitive to the number of patients initiating and completing treatment. The probability of point-of-care Xpert being cost-effective was 90% at a willingness to pay of 3820 per treatment completion. Interpretation: In southern Africa, although point-of-care Xpert unit cost is higher than Lab Xpert, it is likely to offer good value for money relative to smear microscopy. With the current availability of point-of-care nucleic acid amplification platforms (eg, Xpert Edge), these data inform much needed investment and resource allocation strategies in tuberculosis endemic settings.https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(19)30164-0/fulltextPublisher’s versio

    Tuberculosis knowledge, misconceptions/myths in adults: findings from Lesotho, Malawi, Namibia and Zambia Demographic Health Surveys (2013–2016)

    No full text
    Abstract Objective To determine TB knowledge and misconceptions/myths amongst HIV positive and negative adults using Demographic Health Survey data from Lesotho, Malawi, Namibia and Zambia. Results Overall 97% (n = 58,107) of both male and female respondents irrespective of their HIV status had heard of tuberculosis out of whom 82.6% knew that it can be cured. Knowledge that TB is spread in air when coughing or sneezing was 73.8%. Significantly higher proportions of HIV positive men and women than their HIV negative counterparts, had ever heard about TB, knew that it is transmitted through air when coughing and sneezing and also that it can be cured. However interestingly, significantly higher proportions of HIV positive men and women, than their HIV negative counterparts, had the misconception that TB is spread through sharing utensils or would overall say they did not know how it is spread. TB knowledge was significantly higher among individuals who are less than 26 years of age compared to those who were older

    Association between alcohol use and HIV status: findings from Zambia and Zimbabwe

    Get PDF
    Abstract Objective To conduct statistical analysis to assess the association between alcohol use and HIV status using Demographic Health Survey data from Zambia (2013–2014) and Zimbabwe (2015–2016). Results The study showed an association between alcohol use and HIV status using nationally representative population-based surveys. The surveys were conducted among men (15–54 years) and women (15–49 years) in 2013–2014 and 2015–2016 in Zambia and Zimbabwe respectively. HIV prevalence in the two countries was higher among males and females who drank alcohol compared to those who did not. This study reinforces the existing knowledge base on the association between alcohol use and HIV sero-status and calls for further research to explore the causal pathways between alcohol consumption and HIV status

    Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation

    No full text
    Summary: Background: Rapid on-site diagnosis facilitates tuberculosis control. Performing Xpert MTB/RIF (Xpert) at point of care is feasible, even when performed by minimally trained health-care workers, and when compared with point-of-care smear microscopy, reduces time to diagnosis and pretreatment loss to follow-up. However, whether Xpert is cost-effective at point of care remains unclear. Methods: We empirically collected cost (US,2014)andclinicaloutcomedatafromparticipantspresentingtoprimaryhealth−carefacilitiesinfourAfricancountries(SouthAfrica,Zambia,Zimbabwe,andTanzania)duringtheTB−NEATtrial.Costsweredeterminedusinganbottom−upingredientsapproach.Effectivenessmeasuresfromthetrialincludednumberofcasesdiagnosed,initiatedontreatment,andcompletingtreatment.Theprimaryoutcomewastheincrementalcost−effectivenessofpoint−of−careXpertrelativetosmearmicroscopy.Thestudywasperformedfromtheperspectiveofthehealth−careprovider.Findings:Usingdatafrom1502patients,wecalculatedthatthemeanXpertunitcostwaslowerwhenperformedatacentralisedlaboratory(LabXpert)ratherthanatpointofcare(, 2014) and clinical outcome data from participants presenting to primary health-care facilities in four African countries (South Africa, Zambia, Zimbabwe, and Tanzania) during the TB-NEAT trial. Costs were determined using an bottom-up ingredients approach. Effectiveness measures from the trial included number of cases diagnosed, initiated on treatment, and completing treatment. The primary outcome was the incremental cost-effectiveness of point-of-care Xpert relative to smear microscopy. The study was performed from the perspective of the health-care provider. Findings: Using data from 1502 patients, we calculated that the mean Xpert unit cost was lower when performed at a centralised laboratory (Lab Xpert) rather than at point of care (23·00 [95% CI 22·12–23·88] vs 28⋅03[26⋅19–29⋅87]).Per1000patientsscreened,andrelativetosmearmicroscopy,point−of−careXpertcostanadditional28·03 [26·19–29·87]). Per 1000 patients screened, and relative to smear microscopy, point-of-care Xpert cost an additional 35 529 (27 054–40 025) and was associated with an additional 24·3 treatment initiations ([–20·0 to 68·5]; 1464pertreatment),63⋅4same−daytreatmentinitiations([27⋅3–99⋅4];1464 per treatment), 63·4 same-day treatment initiations ([27·3–99·4]; 511 per same-day treatment), and 29·4 treatment completions ([–6·9 to 65·6]; 1211percompletion).Xpertcostsweremostsensitivetotestvolume,whereasincrementaloutcomesweremostsensitivetothenumberofpatientsinitiatingandcompletingtreatment.Theprobabilityofpoint−of−careXpertbeingcost−effectivewas901211 per completion). Xpert costs were most sensitive to test volume, whereas incremental outcomes were most sensitive to the number of patients initiating and completing treatment. The probability of point-of-care Xpert being cost-effective was 90% at a willingness to pay of 3820 per treatment completion. Interpretation: In southern Africa, although point-of-care Xpert unit cost is higher than Lab Xpert, it is likely to offer good value for money relative to smear microscopy. With the current availability of point-of-care nucleic acid amplification platforms (eg, Xpert Edge), these data inform much needed investment and resource allocation strategies in tuberculosis endemic settings. Funding: European Union European and Developing Countries Clinical Trials Partnership
    corecore